| Class | Monoamine oxidase inhibitor |
|---|---|
| Chemistry |
chemically diverse group; eg. tranylcypromine is a substituted amphetamine
|
| Routes of administration |
Oral only |
| Absorption |
Rapidly and completely absorbed; bioavailability ~ 10% (selegiline) to 50% ( moclobemide)
|
| Solubility |
Reasonably water-soluble
|
| Distribution |
VOD=1.75L/kg(tranylcyproimine) to 25 L/kg (selegiline) probably highly protein-bound (eg. to MAO!)
|
| Metabolism |
Extensively metabolised, probably in the liver; some of the metabolites have activity, eg. selegiline is metabolised into amphetamine and methamphetamine.
|
| Elimination |
Minimum renal excretion as unchanged drug
|
| Time course of action |
Half-life is only about 2-4 hours, but this does not have any relationship to the duration of their effect
|
| Target receptor |
Monoamine oxidase A and B |
| Mechanism of action |
By binding to both kinds of monoamine oxidase enzymes MAOIs increases the availability of catecholamine neurotransmitters (i.e. mainly noradrenaline and dopamine). Some do this in a completely irreversible fashion. |
| Clinical effects |
Hypertensive crises, hepatotoxicity, seizures, hypoglycaemia, mania, serotonin syndrome. Dangerous pharmacodynamic interactions with other antidepressants and monoaminergic drugs, as well as foods that act as catecholamine precursors |
| Literature reference |
Ulrich et al (2017) |
| CICM details of understanding | Level 3 |
| Mentioned around Deranged Physiology | |
| Related SAQs |
Question 9(p.2) from the first paper of 2009 (compare and contrast classes) Question 3 from the second paper of 2007 (TCA overdose) |